International Journal of Radiation Oncology * Biology * Physics
Volume 54, Issue 5 , Pages 1550-1557 , 1 December 2002

Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments

  • Mohammed Berrada, Ph.D.

      Affiliations

    • Department of Oncology, McGill University, Montréal, Québec, Canada
    • ,
  • Zhi Yang, Ph.D.

      Affiliations

    • Department of Oncology, McGill University, Montréal, Québec, Canada
    • ,
  • Shirley Lehnert, Ph.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Dr. Shirley Lehnert, Radiation Oncology, McGill University, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada. Tel: (514) 934-1934, ext. 44161; Fax: (514) 934-8220
    • Department of Oncology, McGill University, Montréal, Québec, Canada

Received 10 January 2002 ,Revised 9 July 2002 ,Accepted 10 July 2002.

References 

  1. Grem JL. Mechanisms of action and modulation of fluorouracil. Semin Radiat Oncol. 1997;7:249–259
  2. Scanlon KJ, Newman EM, Lu Y, et al.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian cells. Proc Natl Acad Sci U S A. 1986;83:8923–8925
  3. Rich TA. Irradiation plus 5-fluorouracil (Cellular mechanisms of action and treatment schedules). Semin Radiat Oncol. 1997;7:267–273
  4. Moertel CG, Childs DS, Reitemeier RJ, et al.  Combined 5-fluorouracil and supervoltage radiation therapy of unresectable gastrointestinal cancer. Lancet. 1969;2:865–867
  5. Gunderson LL, Collins R, Earle JD, et al.  Adjuvant treatment of rectal cancer (Randomized prospective study of irradiation ± chemotherapy). Int J Radiat Oncol Biol Phys. 1986;12:169
  6. The Gastroenterology Tumor Study Group . Prolongation of the disease free interval in surgically treated rectal carcinoma. N Engl J Med. 1985;312:1465
  7. The Gastroenterology Tumor Study Group . Survival after post operative combination treatment. (Letter to editor) N Engl J Med. 1986;315:1294
  8. Menei P, Venier M-C, Gamelin E, et al.  Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma. Cancer. 1999;86:324–330
  9. Chaney AW, Eifel PJ, Logsdon MD, et al.  Mature results of a pilot study of pelvic radiotherapy with concurrent continuous infusion intra-arterial 5-FU for stage IIIB-IVA squamous cell carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1999;45:113–118
  10. Dasmahapatra KS, Citrin P, Hill DJ, et al.  A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous cell cancer of the head and neck. J Clin Oncol. 1985;3:1486–1489
  11. Decker DA, Drelichman A, Jacobs J, et al.  Adjunct chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer. 1993;51:1353–1355
  12. Kish JA, Weaver A, Jacobs J, et al.  Cisplatin and 5-fluorouracil infusion in patients with recurrent disseminated epidermoid cancer of the head and neck. Cancer. 1984;53:1819–1824
  13. Mercier RJ, Neal GD, Mattox DE, et al.  Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck. Cancer. 1987;60:2609–2612
  14. Thyss A, Schnieder M, Santini J, et al.  Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer. 1986;54:755–760
  15. Posner MR, Belliveau JF, Weitberg A, et al.  Continuous infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma. Cancer Treat Rep. 1987;71:975–977
  16. Kemeny N, Niedzwiecka D, Reichman B, et al.  Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma (Differences in two patient groups with similar response rates). Cancer. 1989;63:1065–1069
  17. Decker DA, Kinzie J, Evans R, et al.  Pilot study of combination 5-fluorouracil cisdiamminodichl; oroplatinumII, and radiation therapy for grade III and IV astrocytoma. Am J Clin Oncol. 1987;10:444–447
  18. Hidalgo OF, Gonzalez F, Gil A, et al.  120 hours of simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am J Clin Oncol. 1989;12:397–401
  19. Koizumi W, Kurihara M, Sasai T, et al.  A phase II study of combination therapy with 5-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer. 1993;72:658–662
  20. Moertel CG, Rubin J, O’Connell MJ, et al.  A phase II study of combine 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol. 1986;4:1053–1057
  21. Sadek H, Azli N, Wendling JL, et al.  Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil and bleomycin. Cancer. 1990;66:1692–1696
  22. Esaki T, Nakano S, Tatsumoto T, et al.  Inhibition by 5-fluorouracil of cisdiamminodichloroplatinum II-induced DNA interstrand cross-link removal in HST-human squamous cell carcinoma line. Cancer Res. 1992;52:6501–6506
  23. Keane TE, Gingrich JR, Rosner G, et al.  Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer (Analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model). Cancer Res. 1994;54:475–481
  24. Schabel JM, Trader MW, Laster WR, et al.  cis-Dichloroammineplatinum (II) (Combination chemotherapy and cross-resistance studies with tumors of mice). Cancer Treat Rep. 1979;63:1459–1473
  25. Wennerberg J, Biorklund A, Tropé C. The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1988;114:162–167
  26. Leong KW, Brott BC, Langer RJ. Bioerodible poly anhydrides as drug carrier matrices. I. Characterization, degradation and release characteristics. J Biomed Mater Res. 1985;19:00;00
  27. Leong KW, D’Amore P, Marletta M, et al.  Bioerodible polyanhydrides as drug-carrier matrices. Biocompatibility and chemical reactivity. J Biomed Mater Res. 1986;20:51–64
  28. Walter KA, Kahan MA, Gur A, et al.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 1994;54:2207–2212
  29. Sipos EP, Witham TF, Ratan R, et al.  Biothionine sulfoximine potentiates the antitumor effect of 4-hydroxycyclophosphamide when deliver locally in the intracranial 9L-glioma model. Proc Amer Assoc Cancer Res. 1995;36:308
  30. Brem H, Piantadosi S, Burger PC, et al.  Placebo-controlled trial of safety and efficacy of intra-operative controlled delivery by biodegradable polymer of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008–1012
  31. Yapp DTT, Lloyd DK, Zhu J, et al.  Tumor treatment by sustained intra-tumoral release of cisplatin (Effects of drug alone and combined with radiation). Int J Radiat Oncol Biol Phys. 1997;39:497–504
  32. Yapp DTT, Lloyd DK, Zhu J, et al.  The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin. Int J Radiat Oncol Biol Phys. 1998;42:413–420
  33. Yapp DTT, Lloyd DK, Zhu J, et al.  Cisplatin delivery by biodegradable polymer implant, systemic injection and osmotic pump (Differences in selected tissue distribution in C3H mice bearing subcutaneous RIF-1 tumors). Anticancer Drugs. 1998;9:791–796
  34. Yapp DTT, Lloyd DK, Zhu J, et al.  Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device. Radiother Oncol. 1999;53:77–84
  35. Doiron A, Yapp DTT, Olivares M, et al.  Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine. Cancer Res. 1999;59:3677–3681
  36. Twentyman PR, Brown JM, Gray JW, et al.  A new mouse tumor system (RIF-1) for comparison of end-point studies. J Natl Canc Inst. 1980;64:595–604
  37. Brown JM, Twentyman PR, Zamvil SS. Response of the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay and tumor control), chemotherapeutic agents, and activated macrophages. J Natl Canc Inst. 1980;64:605–611
  38. Bernstein M, Gutin PH, Weaver KA, et al.  125I interstitial implants in the RIF-1 murine flank tumor (An animal model for brachytherapy). Radiat Res. 1982;91:624–637
  39. Krishnaswamy V. Dose distribution around an I-125 seed source in tissue. Radiology. 1978;126:489–491
  40. Kirichenko AV, Rich TA, Newman RA, et al.  Potentiation of the murine Mca-4 carcinoma response by 9-amino-20 (s)-camptothecin. Cancer Res. 1997;57:1929–1933
  41. Williams JA, Dillehay LE, Tabassi K, et al.  Implantable biodegradable polymers for IUDR radiosensitization of experimental human malignant glioma. J Neurooncol. 1997;32:181–192
  42. Ewend MG, Williams JA, Tabassi K, et al.  Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain models. Cancer Res. 1996;56:5217–5223
  43. Lana SE, Dernell WS, LaRue SM, et al.  Slow release cisplatin combined with radiation for the treatment of canine nasal tumors. Vet Radiol Ultrasound. 1997;38:474–478
  44. Dela Flor-Weiss E, Uziely B, Muggia FM. Protracted drug infusions in cancer treatment (An appraisal of 5-fluorouracil, doxorubicin, and platinums). Ann Oncol. 1993;4:723–733
  45. Spicer DV, Ardalan B, Daniels JR, et al.  Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res. 1988;48:459–461
  46. Howell SB, Kirmani S, McClay EF, et al.  Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma. Semin Oncol. 1991;18:5–10
  47. Markham M, Reichman B, Hakes T, et al.  Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer. 1993;71(Suppl.):1565–1570
  48. Yu NY, Patawaran MB, Chen JY, et al.  Influence of treatment sequence on efficacy of fluorouracil and cisplatin intra-tumoral drug delivery. Cancer J Sci Am. 1994;1:215–221
  49. Sipos EP, Witham TF, Ratan R, et al.  L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroxyperoxycyclophosphamide when administered locally in a rat glioma model. Neurosurgery. 1995;48:392–400

☆ Supported in part by the National Cancer Institute of Canada and the Cancer Research Society Inc. of Montreal.

PII: S0360-3016(02)03740-9

doi: 10.1016/S0360-3016(02)03740-9

International Journal of Radiation Oncology * Biology * Physics
Volume 54, Issue 5 , Pages 1550-1557 , 1 December 2002

Article Tools

* Image Usage & Resolution